Amy B. Heimberger

30.4k total citations · 11 hit papers
272 papers, 17.5k citations indexed

About

Amy B. Heimberger is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Amy B. Heimberger has authored 272 papers receiving a total of 17.5k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 116 papers in Immunology and 104 papers in Genetics. Recurrent topics in Amy B. Heimberger's work include Glioma Diagnosis and Treatment (103 papers), Cancer Immunotherapy and Biomarkers (63 papers) and Immunotherapy and Immune Responses (53 papers). Amy B. Heimberger is often cited by papers focused on Glioma Diagnosis and Treatment (103 papers), Cancer Immunotherapy and Biomarkers (63 papers) and Immunotherapy and Immune Responses (53 papers). Amy B. Heimberger collaborates with scholars based in United States, China and Australia. Amy B. Heimberger's co-authors include Kenneth M. Murphy, Dennis Y. Loh, John H. Sampson, Jun Wei, Kenneth Aldape, Raymond Sawaya, Ling-Yuan Kong, Dima Suki, Gregory N. Fuller and David Yang and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Amy B. Heimberger

265 papers receiving 17.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Induction by Antigen of Intrathymic Apoptosis of CD4 ⁺ CD8 ⁺ TCR ^lo Thymocytes in Vivo

1990 1.6k citations Amy B. Heimberger et al. profile →
Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system.

1992 653 citations Amy B. Heimberger et al. profile →
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

2010 613 citations John H. Sampson, Amy B. Heimberger et al. Journal of Clinical Oncology profile →
Glioma cancer stem cells induce immunosuppressive macrophages/microglia

2010 522 citations Adam Wu, Jun Wei et al. Neuro-Oncology profile →
PD-L1 expression and prognostic impact in glioblastoma

2015 457 citations Jun Wei, Ling-Yuan Kong et al. Neuro-Oncology profile →
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

2015 313 citations David A. Reardon, Amy B. Heimberger et al. Neuro-Oncology profile →
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

2017 308 citations Martina Ott, Shouhao Zhou et al. Neuro-Oncology profile →
Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target

2018 287 citations Jun Wei, Anantha Marisetty et al. Journal of Clinical Investigation profile →
Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy

2023 211 citations Fatima Khan, Lizhi Pang et al. Journal of Clinical Investigation profile →
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment

2023 148 citations Víctor A. Arrieta, Crismita Dmello et al. Journal of Clinical Investigation profile →
Crossing the blood–brain barrier: emerging therapeutic strategies for neurological disease

2025 22 citations Adam M. Sonabend, Amy B. Heimberger et al. profile →

Peers

Countries citing papers authored by Amy B. Heimberger

Since Specialization

Citations

This map shows the geographic impact of Amy B. Heimberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy B. Heimberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy B. Heimberger more than expected).

Fields of papers citing papers by Amy B. Heimberger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy B. Heimberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy B. Heimberger. The network helps show where Amy B. Heimberger may publish in the future.

Co-authorship network of co-authors of Amy B. Heimberger

This figure shows the co-authorship network connecting the top 25 collaborators of Amy B. Heimberger. A scholar is included among the top collaborators of Amy B. Heimberger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy B. Heimberger. Amy B. Heimberger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-child phase I trial of p-STAT3 inhibitor WP1066 in pediatric brain tumor patients 2025 ·JCI Insight ·Robert C. Castellino, Hope Mumme, Andrea Franson, (unknown), (unknown), Kavita M. Dhodapkar, Dolly Aguilera, Matthew Schniederjan, (unknown), (unknown), Manoj Bhasin, Waldemar Priebe, Amy B. Heimberger, Tobey J. MacDonald	0
2	Immune Checkpoint Inhibitors in Glioblastoma IDHwt Treatment: A Systematic Review 2024 ·Cancers ·(unknown), (unknown), (unknown), Derek A. Wainwright, Adam M. Sonabend, Amy B. Heimberger, Rimas V. Lukas	3
3	FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells 2023 ·Nature Communications ·Qingnan Zhao, Jiemiao Hu, Ling‐Yuan Kong, Shan Jiang, Xiangjun Tian, Jing Wang, Rintaro Hashizume, Zhiliang Jia, Natalie W. Fowlkes, Jun Yan, Xueqing Xia, (unknown), (unknown), David Masopust, Amy B. Heimberger, Shulin Li	16
4	Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas 2023 ·PubMed ·Andrew Gould, (unknown), Crismita Dmello, (unknown), Rimas V. Lukas, Daniel Y. Zhang, Amy B. Heimberger, Michael Canney, Alexandre Carpentier, Carole Desseaux, Guillaume Bouchoux, Roger Stupp, Adam M. Sonabend	8
5	Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment breakdown → 2023 ·Journal of Clinical Investigation ·Víctor A. Arrieta, Crismita Dmello, Daniel J. McGrail, Daniel J. Brat, Catalina Lee-Chang, Amy B. Heimberger, Dhan Chand, Roger Stupp, Adam M. Sonabend	148
6	TMIC-58. ALTERATIONS IN GLIOBLASTOMA TUMOR MICROENVIRONMENT TRANSCRIPTOME AFTER TREATMENT WITH PEMBROLIZUMAB 2023 ·Neuro-Oncology ·Nazanin Majd, Yang Liu, (unknown), Kristin Alfaro-Munoz, (unknown), Amy B. Heimberger, Kasthuri Kannan, Jason T. Huse, Krishna Bhat, John de Groot	1
7	Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma 2022 ·Cancer Immunology Research ·Wenjing Xuan, Wen-Hao Hsu, Fatima Khan, Madeline Dunterman, Lizhi Pang, Derek A. Wainwright, Atique U. Ahmed, Amy B. Heimberger, Maciej S. Lesniak, Peiwen Chen	80
8	Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma 2021 ·Clinical Cancer Research ·C. Elizabeth Boudreau, Hinda Najem, Martina Ott, Craig Horbinski, Dexing Fang, (unknown), Jonathan M. Levine, Michael A. Curran, Amy B. Heimberger	34
9	Anti–PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells 2020 ·Clinical Cancer Research ·Ganesh Rao, Khatri Latha, Martina Ott, Aria Sabbagh, Anantha Marisetty, Xiaoyang Ling, Daniel Zamler, Tiffany Doucette, Yuhui Yang, Ling‐Yuan Kong, Jun Wei, Gregory N. Fuller, Fernando Benavides, Adam M. Sonabend, James P. Long, Shulin Li, Michael A. Curran, Amy B. Heimberger	80
10	Radiation with STAT3 Blockade Triggers Dendritic Cell–T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy 2020 ·Clinical Cancer Research ·Martina Ott, Cynthia Kassab, Anantha Marisetty, Yuuri Hashimoto, Jun Wei, Daniel Zamler, Jia-Shiun Leu, Karl-Heinz Tomaszowski, Aria Sabbagh, Dexing Fang, Pravesh Gupta, Waldemar Priebe, Rafał Zieliński, Jared K. Burks, James P. Long, Ling-Yuan Kong, Gregory N. Fuller, John DeGroot, Erik P. Sulman, Amy B. Heimberger	41
11	miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis 2016 ·Cancer Research ·Jianfei Xue, Aidong Zhou, Yamei Wu, (unknown), Kangyu Lin, Samirkumar B. Amin, Roeland Verhaak, Gregory N. Fuller, Keping Xie, Amy B. Heimberger, Suyun Huang	76
12	FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells 2015 ·Cancer Research ·(unknown), Ping Wei, Sicong Zhang, Jun Yao, Ying Yuan, Aidong Zhou, Frederick F. Lang, Amy B. Heimberger, Ganesh Rao, Suyun Huang	79
13	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity 2015 ·Cancer Research ·Hillary G. Caruso, Lenka V. Hurton, Amer Najjar, David Rushworth, Sonny Ang, Simon Olivares, Tiejuan Mi, Kirsten C. Switzer, Harjeet Singh, Helen Huls, Dean A. Lee, Amy B. Heimberger, Richard E. Champlin, Laurence J.N. Cooper	324
14	Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy 2014 ·Cancer Immunology Research ·Brett Schrand, Alexey Berezhnoy, Randall Brenneman, Anthony Williams, Agata Levay, Ling-Yuan Kong, Ganesh Rao, Shouhao Zhou, Amy B. Heimberger, Eli Gilboa	72
15	miR-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma 2013 ·Cancer Research ·Jun Wei, Fei Wang, Ling-Yuan Kong, Shuo Xu, Tiffany Doucette, Sherise D. Ferguson, Yuhui Yang, Kayla McEnery, Krishan R. Jethwa, Olsi Gjyshi, Wei Qiao, Nicholas B. Levine, Frederick F. Lang, Ganesh Rao, Gregory N. Fuller, George A. Călin, Amy B. Heimberger	209
16	Glioma-Associated Cytomegalovirus Mediates Subversion of the Monocyte Lineage to a Tumor Propagating Phenotype 2011 ·Clinical Cancer Research ·Kristine Dziurzynski, Jun Wei, Wei Qiao, Mustafa Aziz Hatiboğlu, Ling-Yuan Kong, Adam Wu, Yongtao Wang, Daniel P. Cahill, Nicholas B. Levine, Sujit S. Prabhu, Ganesh Rao, Raymond Sawaya, Amy B. Heimberger	111
17	Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma breakdown → 2010 ·Journal of Clinical Oncology ·John H. Sampson, Amy B. Heimberger, Gary E. Archer, Kenneth Aldape, Allan H. Friedman, Henry S. Friedman, Mark R. Gilbert, James E. Herndon, Roger E. McLendon, Duane A. Mitchell, David A. Reardon, Raymond Sawaya, Robert J. Schmittling, Weiming Shi, James J. Vredenburgh, Darell D. Bigner	613
18	An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme 2009 ·Molecular Cancer Therapeutics ·John H. Sampson, Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, James E. Herndon, Denise Lally-Goss, (unknown), (unknown), David A. Reardon, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner	221
19	A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients 2007 ·Cancer Research ·S. Farzana Hussain, Ling-Yuan Kong, (unknown), Charles A. Conrad, Timothy Madden, (unknown), Waldemar Priebe, Amy B. Heimberger	246
20	Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma 2007 ·Journal of Clinical Oncology ·Christopher E. Pelloski, Karla V. Ballman, Alfred Furth, Li Zhang, E. Lin, Erik P. Sulman, Krishna Bhat, J. Matthew McDonald, W.K. Alfred Yung, Howard Colman, Shiao Y. Woo, Amy B. Heimberger, Dima Suki, Michael D. Prados, Susan M. Chang, Fred G. Barker, Jan C. Buckner, C. David James, Kenneth Aldape	239

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact